PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) – Final assessment now available

This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In August, 2020, the European Commission granted marketing authorisation for pretomanide (pretomanid FGK) in combination with bedaquiline and linezolid for the treatment […]

OTCA26 Obesity Surgery Project – Project Plan now available

EUnetHTA is pleased to announce the project description and planning for 26th Other Technologies Collaborative Assessment “Surgical procedures for treatment of obesity” is now available for access. The relevance of the topic lies in evidence suggesting that bariatric surgery decreases the risk of premature death and other physical morbidities, but the effectiveness and safety of […]

OTCA23 Final Assessment Report “Biodegradable rectum spacers to reduce toxicity for prostate cancer” now available

The Other Technologies Collaborative Assessment OTCA23 final assessment report “Biodegradable rectum spacers to reduce toxicity for prostate cancer”, together with related documentation, is now available for access. The assessed technology is biodegradable rectum spacers added to conventional radiotherapy to (temporarily) position the prostate away from the rectum with the aim of reducing the side effects […]

PTJA12 – Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy – Final assessment now available

This is the pharmaceutical Joint Assessment PTJA12 – on glasdegib for the treatment of acute myeloid leukaemia (AML). In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary AML in adult patients who are not candidates for standard […]

EUnetHTA Covid-19 Response

To help in the development of a coordinated response to the Covid-19 pandemic, it is essential that researched, timely and reliable information can be made available to all stakeholders, whether healthcare professionals or members of the public. With this in mind, EUnetHTA has taken the decision to prioritise Covid-19-related initiatives above other work for the […]

EUnetHTA Open Call for Early Dialogue Requests

The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open Call will remain open from July 3, 2020 through to August 15, 2020. Once […]

EUnetHTA Early Dialogues – Status during EUnetHTA prolongation period

The current pandemic situation has put additional strain on European health systems and HTA bodies have not been immune to this impact. The unfortunate result of this has been the temporary suspension of EUnetHTA Early Dialogues (EDs).​ We are pleased to announce that the EUnetHTA Executive Board has recognized the interest to continue to offer […]

RCR OT 01 – “Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic” – final assessment now available

EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic” is now available.  This is the first rapid review assessing health technologies for SARS-CoV-2. The general objective of this assessment was to provide a reliable synthesis of the […]

OTCA21 ‘Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea’ Final Assessment now available

EUnetHTA is pleased to announce that the OTCA21 Final Assessment is now available for access. The assessed technology is Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea. The aim of this assessment was to evaluate effectiveness and safety of HGNS compared with no treatment in those adult patients with moderate-to-severe obstructive sleep apnea […]

PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options – Final assessment now available

This is the pharmaceutical Joint Assessment PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. In April 2020, the European Commission granted marketing authorisation for Fetcroja® (cefiderocol) for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. […]